A St. Louis Circuit Court judge gave final approval on November 20 to Bayer's $7.25 billion settlement of claims that its Roundup weedkiller causes non-Hodgkin lymphoma. Judge Timothy Boyer called the agreement fair, reasonable, and adequate, and described it as among the largest mass tort personal-injury settlements in U.S. history.
The settlement covers about 65,000 current U.S. claimants, along with people who were exposed before the agreement and are diagnosed in the future. Bayer continues to deny that Roundup causes cancer. A settlement resolves claims; it is not a finding of liability.
The terms
Individual payments are expected to average between $10,000 and $165,000, depending on whether the exposure was residential or occupational, the claimant's age at diagnosis, and the severity of the illness. The fund will pay claims over a period of up to 21 years.
The agreement includes about $600 million in attorneys' fees. The payments are structured to spread the cost over decades, which is one reason the total is large while the individual amounts are more modest.
The judge's approval is the final step in the class settlement process, and it is subject to appeal. Claimants who object to the terms can challenge the approval, and the appellate courts can review it.
How the litigation began
The modern wave of Roundup litigation began after the World Health Organization's cancer agency classified glyphosate as probably carcinogenic in 2015. The classification did not ban the product, and it did not establish that every exposure causes cancer. It did give plaintiffs a scientific argument that a jury could hear.
The first trials produced large verdicts against Bayer, which had acquired Roundup when it bought Monsanto in 2018. The company appealed, and some of the awards were reduced or overturned. The litigation continued for years, and the settlement talks became a recurring feature of Bayer's investor calls.
The 2020 settlement resolved a large share of the claims, and it did not end the litigation. New claims continued to arrive, and the legal theories evolved. The 2026 settlement is an attempt to close the remaining U.S. class claims.
The economics for Bayer
Bayer has set aside about $16 billion in total for Roundup litigation, and the $7.25 billion settlement is the largest single piece. The charge has weighed on the company's earnings and on its share price for years.
A settlement converts an uncertain liability into a known cost. The company can plan around a fixed payment schedule, and it can stop spending on trials and appeals. The tradeoff is that the payment is large and the fund will exist for decades.
The company's investors will watch how the settlement is funded and whether it affects the dividend or the balance sheet. Bayer has said the settlement is manageable, and the market will test that claim.
The legal backdrop
The settlement follows a Supreme Court decision in June 2026 that changed the landscape for the litigation. In a 7 to 2 ruling in the Durnell case, the Court held that federal pesticide law preempts state-law claims that a manufacturer failed to warn of a health risk. The ruling sharply weakened the plaintiffs' ability to bring failure-to-warn claims.
Bayer had already settled a large share of the litigation. The company reached a roughly $10.9 billion settlement in 2020, and it has set aside about $16 billion in total for Roundup claims. The new agreement adds to that total and is intended to resolve the remaining U.S. claims.
The preemption ruling is the reason the settlement is structured as it is. With the failure-to-warn theory narrowed, the plaintiffs' leverage was reduced, and the settlement reflects that balance.
The reaction
Bayer's chief executive, Bill Anderson, called the approval a decisive milestone. The plaintiffs' lead counsel, Christopher Seeger, welcomed the approval. Some plaintiffs' attorneys objected, arguing that the payouts are too low and the terms too restrictive, particularly for people who are terminally ill.
Judge Boyer addressed the objections in his ruling. He noted the risk that Bayer could have sought bankruptcy protection if the settlement had been rejected, and he warned that a rejection would have delayed payments for claimants who are dying. Those considerations are part of the reason he found the agreement fair.
Bayer's statement emphasized that the company continues to believe its product is safe. The settlement does not change that position, and the company has said it will continue to defend the product.
The settlement mechanics
The settlement is structured as a class settlement with a claims process. Claimants submit evidence of their diagnosis and their exposure, and the fund pays according to a schedule that accounts for the factors in the agreement.
The class covers current claimants and people who were exposed before a defined date and are diagnosed in the future. The future-claims provision is one of the more unusual parts of the agreement, and it is why the fund is designed to last for up to 21 years.
Claimants who object to the settlement can appeal the approval. The appellate courts can affirm, reverse, or modify the approval, and the process can take a year or more.
The science
The question of whether Roundup causes non-Hodgkin lymphoma has been contested for years. Plaintiffs point to studies and to the World Health Organization's cancer agency, which classified glyphosate as probably carcinogenic. Bayer and other defenders point to regulatory reviews in the United States and Europe that have found the product safe when used as directed.
The scientific disagreement is one reason the litigation has been so long and so expensive. A settlement does not resolve the science. It resolves the claims, and it allows both sides to avoid the uncertainty of further trials.
The regulatory picture also matters. The Environmental Protection Agency has maintained that glyphosate is safe when used according to its label, and the European Union has extended its approval. Those positions are not the same as a finding that the product cannot cause cancer in every case.
What it means for claimants
Claimants who are part of the settlement will receive payments under the fund's schedule. The payments will be spread over years, and the amount depends on the factors in the agreement.
Claimants who opted out or who are not covered will have to pursue their claims separately. The roughly 200 federal cases that remain pending are part of that group.
The appeals process could delay payments. An appeal of the approval would pause the settlement while the appellate court reviews it, and the outcome could change the terms.
The regulatory debate
The EPA has maintained that glyphosate is safe when used according to its label, and the European Union has extended its approval. The WHO agency's classification is a hazard assessment, which asks whether a substance could cause cancer under some circumstances, not whether it does cause cancer at real-world exposure levels.
Those two kinds of assessment are often confused in public debate. A hazard classification can be true even when the risk at ordinary exposure is low. A risk assessment can conclude that the product is safe even when the hazard exists at high doses.
The distinction matters for the settlement and for the public. The plaintiffs' claims are about their individual exposures; the regulators' reviews are about populations. A settlement does not resolve which frame is correct.
What remains
The settlement resolves the U.S. claims that are part of the class, and it does not resolve the debate about the product. Bayer faces other litigation, and the regulatory and scientific questions will continue.
The company's total exposure is now more predictable. That is the point of a mass settlement: it converts an open-ended liability into a known cost. For Bayer, the cost is $7.25 billion plus the earlier settlements. For the claimants, the benefit is a payment without a trial.
The claimants' view
For a claimant with non-Hodgkin lymphoma, the settlement offers a payment without the uncertainty of a trial. The amount depends on the factors in the schedule, and the payment is spread over time.
Some claimants and their lawyers argue that the amounts are too low, especially for people with advanced illness. The objectors raised that point at the approval hearing, and the judge weighed it against the risk of a bankruptcy that would have delayed payments further.
The settlement does not require Bayer to admit that Roundup caused any claimant's illness. That is a standard feature of mass tort settlements, and it is a source of frustration for plaintiffs who wanted a finding of liability.
The mass tort model
The Roundup settlement is a case study in how mass tort litigation ends. A large number of claims, a contested scientific question, a long trial history, and a defendant with the resources to litigate for years produce a settlement that resolves the claims without resolving the science.
The model has been used in asbestos, tobacco, opioids, and other mass torts. It provides compensation and finality, and it leaves the underlying questions to regulators and researchers.
The Roundup case is unusual because the product is still on the market and the regulatory debate is still active. A settlement that resolves the claims does not resolve the public argument about the product.
A settlement, not a verdict
The judge's approval is a milestone in one of the longest-running product-liability sagas in American law. It is not a verdict, and it does not settle the science.
The agreement gives claimants a path to compensation and gives the company a measure of certainty. It does not end the argument about the product, and it does not answer the scientific question. It is a legal resolution, and the law and the science will continue on separate tracks. For now, the settlement is the outcome. For the claimants, the next step is the claims process; for Bayer, it is the payment schedule and the appeals. The appeals and the remaining cases will determine how much of that certainty holds.
Primary sources
- The Guardian, for the approval, the terms, and the judge's ruling.
- BBC News, for the settlement size and the reactions.
- USA Today, for the Missouri court details and the claimant figures.
- The Associated Press, via KY3, for the procedural history and the Durnell ruling.